Please assess the completion status of the following clinical trial:

Trial Title: Brain Imaging Techniques That Predict Antidepressant Responsiveness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Intervention Group:~  * Right-handed,~ * Be able to lie still on their back for about 120 minutes,~ * Meet DSM-IV criteria for major depression (single or recurrent),~ * Have had depressive symptoms for at least 1 month prior to screen visit,~ * Must score an 18 or above on the Hamilton-D at both the initial screening visit and first fMRI scanning session,~ * Able to understand and speak English.~* Control Group: same as above with the exception of no diagnosis of psychiatric disorder.~Exclusion Criteria:~* Any history of seizures,~* Current medical disorders that might make interpretation of scan data difficult,~* Diabetes requiring insulin treatment,~* A serious heart disorder or subjects who have had a heart attack within the last 3 months,~* Subjects who meet DSM-IV criteria for alcohol/drug abuse or dependence within the last six months,~* Other current DSM-IV Axis I or Axis II diagnoses,~* A personal or family history of bipolar disorder,~* Current use of medication that affects central nervous system (CNS) function,~* Participation in the last 30 days in a clinical study involving an investigational drug,~* A subject with metallic implants, such as prostheses, shrapnel or aneurysm clip-S, or persons with electronic implants, such as cardiac pacemakers. The magnetic field generated by the MRI machine can cause a displacement or malfunctioning of these devices.~* A subject who is claustrophobic,~* Female subjects who are pregnant,~* A subject at serious risk for suicide,~* Diagnosis of cancer in the past 3 years and/or has active neoplastic disease,~* Nonresponse to 2 adequate trials of antidepressant treatment,~* Nonresponse to 2 adequate trials of an empirically supported psychotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Depressed; Venlafaxine treatment (Type: ACTIVE_COMPARATOR): Currently depressed subjects; Randomized medication treatment with Venlafaxine extended release tablets (Venlafaxine ERT). Dosage 75-300mg/day for up to 6 months.
- Depressed; Fluoxetine treatment (Type: ACTIVE_COMPARATOR): Currently depressed subjects; Randomized medication treatment with Fluoxetine tablets. Dosage 20-80mg/day for up to 6 months.
- Control (Type: NO_INTERVENTION): Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication

Based on this trial design, predict the completion outcome and termination type (if applicable).